TNDM — Tandem Diabetes Care, Inc. stock price, charts and financials

Latest market price

20.20

+0.09+0.45%

Overview Short InterestFilings

TNDMQT58Tandem Diabetes Care, Inc.·NASDAQ

Overview Short InterestFilings

20.20+0.45%

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

IART+0.11%$17.90 AORT-2.08%$26.90 CNMD-2.82%$50.40 ATEC+1.97%$10.35 IRMD+1.71%$93.13 AVNS+0.04%$24.99 ENOV-1.78%$30.86 PRCT-0.54%$18.28

Snapshot

Index	-	P/E	-	EPS (ttm)	-1.40	Insider Own	1.31%	Shs Outstand	68.53M	Perf Week	13.74%

Market Cap	1.38B	Forward P/E	159.04	EPS next Y	0.13	Insider Trans	-0.02%	Shs Float	62.92M	Perf Month	31.00%

Enterprise Value	1.53B	PEG	-	EPS next Q	-	Inst Own	-	Short Float	20.84%	Perf Quarter	1.66%

Income	-94.00M	P/S	1.35	EPS this Y	51.93%	Inst Trans	-	Short Ratio	5.54	Perf Half Y	0.55%

Sales	1.03B	P/B	10.49	EPS next Y	118.87%	ROA	-8.20%	Short Interest	13.12M	Perf YTD	-8.10%

Book/sh	1.93	P/C	2.43	EPS next 5Y	-	ROE	-68.29%	52W High	29.65 -31.87%	Perf Year	31.17%

Cash/sh	8.32	P/FCF	-	EPS past 3/5Y	-	ROIC	-8.44%	52W Low	9.98 102.40%	Perf 3Y	-43.37%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	8.21% 15.26%	Gross Margin	54.93%	Volatility	5.72% 5.87%	Perf 5Y	-80.21%

Dividend TTM	-	EV/Sales	1.49	EPS Y/Y TTM	4.76%	Oper. Margin	-7.88%	ATR (14)	1.04	Perf 10Y	-73.46%

Dividend Ex-Date	-	Quick Ratio	3.07	Sales Y/Y TTM	9.26%	Profit Margin	-9.20%	RSI (14)	71.48	Recom	2.38

Dividend Gr. 3/5Y	-	Current Ratio	3.58	EPS Q/Q	55.22%	SMA20	16.98%	Beta	1.50	Target Price	29.59

Payout	0.00%	Debt/Eq	2.74	Sales Q/Q	5.56%	SMA50	20.87%	Rel Volume	1.16	Prev Close	20.11

Employees	2,500	LT Debt/Eq	2.74	Earnings	Aug 06	SMA200	5.94%	Avg Volume	2.43M	Price	20.20

IPO Date	Nov 14, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	32.38% 2.83%	Net Debt/EBITDA	-7.73	Volume	2,822,117	Change	0.45%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-28-26	Resumed	UBS	Neutral	$22 → $18
Jun-23-26	Downgrade	Deutsche Bank	Buy → Hold	$16
Jun-01-26	Upgrade	Wells Fargo	Equal Weight → Overweight	$45 → $27
May-27-26	Reiterated	Goldman Sachs	Neutral	$24 → $21
May-11-26	Reiterated	Barclays	Overweight	$56 → $55
May-08-26	Reiterated	Mizuho Securities	Neutral	$22 → $24
Apr-24-26	Reiterated	Redburn Partners		$36 → $45
Mar-19-26	Upgrade	Truist Securities	Hold → Buy
Mar-17-26	Upgrade	Piper Sandler	Neutral → Overweight
Feb-23-26	Reiterated	Goldman Sachs	Neutral	$25 → $28

Latest News

Jul-16-26

Jul-16-2612:35PM

Carlsmed Announces Aprevo Bi-Lateral Posterior Lumbar Interbody Fusion ProcedureBenzinga

Jul-07-26

Jul-07-2611:01AM

Does TNDM Stock Still Deserve a Place in Your Portfolio?zacks.com

Jul-01-26

Jul-01-2608:30AM

Tandem Diabetes Care Launches t:slim X2 Insulin Pump Compatibility with Abbott FreeStyle Libre 3 Plus Sensor in Five International Marketsbusinesswire.com

Jun-30-26

Jun-30-2609:00AM

Tandem Diabetes Care to Announce Second Quarter 2026 Financial Results on August 6, 2026gurufocus.com

Jun-23-26

Jun-23-2609:47AM

This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For TuesdayBenzinga

09:24AM

Deutsche Bank Initiates Coverage On Tandem Diabetes Care with Hold Rating, Announces Price Target of $15.5Benzinga

Company

Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	1,027	1,015	940	748	801	703	499	362	184
Cost of Goods Sold Incl. D&A	463	484	451	380	388	327	238	168	94
Gross Profit	564	531	490	368	413	376	261	194	90
Selling, General and Administrative Excl. Other	437	434	390	353	336	262	205	166	105
Research and Development	188	175	199	248	170	92	64	45	29
Other Operating Expense	20	0	0	0	0	0	-1	0	0
Operating Income	-81	-78	-99	-233	-93	23	-8	-17	-45
Interest Expense	9	8	7	10	6	6	13	0	8
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-9	-114	15	23	6	-1	-16	-8	-70
Net Income Before Taxes	-98	-200	-92	-220	-93	16	-36	-25	-123
Income Taxes	-3	4	4	2	2	0	-2	0	0
Consolidated Net Income	-94	-205	-96	-223	-95	16	-34	-25	-123
Net Income From Continuing Operations	-94	-205	-96	-223	-95	16	-34	-25	-123
Net Income	-94	-205	-96	-223	-95	16	-34	-25	-123
EPS (Recurring)	-1.40	-3.04	-1.47	-3.43	-1.47	0.25	-0.56	-0.42	-2.55
EPS (Basic, Before Extraordinaries)	-1.40	-3.04	-1.47	-3.43	-1.47	0.25	-0.56	-0.42	-2.55
EPS (Diluted)	-1.40	-3.04	-1.47	-3.43	-1.47	0.24	-0.56	-0.42	-2.55
EBITDA	-73	-175	-99	-196	-74	34	-13	-18	-109
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	627.17	—	—	—
Price To Sales Ratio	1.34	1.45	2.49	2.57	3.59	13.49	11.70	9.72	9.91
Gross Margin	54.92	52.32	52.13	49.20	51.56	53.49	52.30	53.59	48.91
Operating Margin	-7.89	-7.68	-10.53	-31.15	-11.61	3.27	-1.60	-4.70	-24.46
Net Margin	-9.15	-20.20	-10.21	-29.81	-11.86	2.28	-6.81	-6.91	-66.85
Shares Outstanding	68	67	65	65	64	63	61	59	48
Market Capitalization	1,374	1,473	2,341	1,923	2,877	9,483	5,836	3,517	1,823
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	#Shares	#Shares Total	SEC Form 4
Kyrillos Jean-Claude	EVP & Chief Operating Officer	Jul 15 '26	Option Exercise	3,636	31,741	Jul 17
McGroddy-Goetz Kathleen	Director	May 21 '26	Option Exercise	8,759	26,612	May 22
ROBERTSON REBECCA B	Director	May 21 '26	Option Exercise	8,759	22,542	May 22
Allen Dick	other: Chair Emeritus	May 21 '26	Option Exercise	8,759	28,146	May 22
Howell Peyton R	Director	May 21 '26	Option Exercise	8,759	29,836	May 22
Malagueira Joao Paulo Falcao	Director	May 21 '26	Option Exercise	8,759	22,458	May 22
TWOMEY CHRISTOPHER J	Director	May 21 '26	Option Exercise	8,759	24,434	May 22
Cha Myoungil	Director	May 21 '26	Option Exercise	8,759	22,458	May 22
Sodhi Rajwant	Director	May 21 '26	Option Exercise	8,759	24,280	May 22
Morrison Susan	EVP & Chief Admin. Officer	May 15 '26	Option Exercise	9,523	51,414	May 19
Sheridan John F	PRESIDENT & CEO	May 15 '26	Option Exercise	51,189	170,051	May 19
Vosseller Leigh	EVP & CHIEF FINANCIAL OFFICER	May 15 '26	Option Exercise	13,495	51,829	May 19
Novara Mark David	EVP & CHIEF COMMERCIAL OFFICER	May 15 '26	Option Exercise	10,572	48,171	May 19
Carpenter Rick	EVP & Chief Technology Officer	May 15 '26	Option Exercise	8,774	32,859	May 19
Gasser Elizabeth Anne	EVP, Chief Strategy Officer	May 15 '26	Option Exercise	10,267	9,937	May 19

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.